In the first ever phase 3 trial of MDMA for Posttraumatic Stress Disorder (PTSD), it was reported that 67% of the group who received MDMA, compared to 32% of the group who received placebo, no longer qualified for a PTSD diagnosis after three MDMA treatment sessions. Now, a second Phase 3 clinical trial is nearing completion with a possibility of MDMA becoming an available treatment in the near future. The aim of this recording is to prepare clinicians with an understanding of MDMA-assisted psychotherapy for PTSD in light of this eventuality.
Planning Committee Disclosure - No relevant relationships
All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.
PESI Australia, in collaboration with PESI in the USA, offers quality online continuing professional development events from the leaders in the field at a standard recognized by professional associations including psychology, social work, occupational therapy, alcohol and drug professionals, counselling and psychotherapy. On completion of the training, a Professional Development Certificate is issued after the individual has answered and submitted a quiz and course evaluation. This program is worth 1.25 hours CPD for points calculation by your association.
|Number of pages
|Manual - MDMA-Assisted Therapy in the Treatment of Posttraumatic Stress Disorder (2.3 MB)
|Available after Purchase
|Transcript (35.6 KB)
|Available after Purchase
Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist and supervisor on the same study. He is co-author on a Nature Medicine paper reporting the results of the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Dr. Gorman has also published on the topics of classic psychedelics, ketamine, and Psychedelic Harm Reduction and Integration.
Please wait ...